Eder Gambeta

Dr. Eder Gambeta

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2020 in Molecular Pain
Verified
Journal Article
Open access
PDF file
EGEder Gambeta
Eder Gambeta
JCJuliana G. Chichorro
Juliana G. Chichorro
GZGerald Zamponi
Gerald Zamponi
The trigeminal nerve (V) is the fifth and largest of all cranial nerves, and it is responsible for detecting sensory stimuli that arise from the craniofacial area. The nerve is divided into three branches: ophthalmic (V1), maxillary (V2), and mandibular (V3); their cell bodies are located in the trigeminal ganglia and they make connections with second-order neurons in the trigeminal brainstem sensory nuclear complex. Ascending projections via the trigeminothalamic tract transmit information to the thalamus and other brain regions responsible for interpreting sensory information. One of the most common forms of craniofacial pain is trigeminal neuralgia. Trigeminal neuralgia is characterized by sudden, brief, and excruciating facial pain attacks in one or more of the V branches, leading to a severe reduction in the quality of life of affected patients. Trigeminal neuralgia etiology can be classified into idiopathic, classic, and secondary. Classic trigeminal neuralgia is associated with neurovascular compression in the trigeminal root entry zone, which can lead to demyelination and a dysregulation of voltage-gated sodium channel expression in the membrane. These alterations may be responsible for pain attacks in trigeminal neuralgia patients. The antiepileptic drugs carbamazepine and oxcarbazepine are the first-line pharmacological treatment for trigeminal neuralgia. Their mechanism of action is a modulation of voltage-gated sodium channels, leading to a decrease in neuronal activity. Although carbamazepine and oxcarbazepine are the first-line treatment, other drugs may be useful for pain control in trigeminal neuralgia. Among them, the anticonvulsants gabapentin, pregabalin, lamotrigine and phenytoin, baclofen, and botulinum toxin type A can be coadministered with carbamazepine or oxcarbazepine for a synergistic approach. New pharmacological alternatives are being explored such as the active metabolite of oxcarbazepine, eslicarbazepine, and the new Nav1.7 blocker vixotrigine. The pharmacological profiles of these drugs are addressed in this review.

1 February 2017 in Neuroscience Letters
Verified
Journal Article
Closed access
JSJonas G. Silva
Jonas G. Silva
ABAna C. Boareto
Ana C. Boareto
ASAnne K. Schreiber
Anne K. Schreiber
DRDaiany D.B. Redivo
Daiany D.B. Redivo
EGEder Gambeta
Eder Gambeta
PDPaulo R. Dalsenter
Paulo R. Dalsenter

1 July 2018 in Physiology & Behavior
Verified
Journal Article
Closed access
EGEder Gambeta
Eder Gambeta
MBMarcio Augusto Batista
Marcio Augusto Batista
GMGabriel Paz Maschio
Gabriel Paz Maschio
JTJoelle de Melo Turnes
Joelle de Melo Turnes
EAErika Ivanna Araya
Erika Ivanna Araya
JCJuliana Geremias Chichorro
Juliana Geremias Chichorro

1 October 2019 in Bioorganic Chemistry
Verified
Journal Article
Closed access
HCHande Aygün Cevher
Hande Aygün Cevher
DSDavid Schaller
David Schaller
Maria A. GandiniMaria A. Gandini
Maria A. Gandini
OKOzan Kaplan
Ozan Kaplan
EGEder Gambeta
Eder Gambeta
MGMiyase Gözde Gündüz
Miyase Gözde Gündüz

1 February 2019 in Behavioural Brain Research
Verified
Journal Article
Closed access
CSCamila Pasquini de Souza
Camila Pasquini de Souza
EGEder Gambeta
Eder Gambeta
CSCristina Aparecida Jark Stern
Cristina Aparecida Jark Stern
JZJanaina Menezes Zanoveli
Janaina Menezes Zanoveli

25 November 2015 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
EGEder Gambeta
Eder Gambeta
CSCamila Pasquini de Souza
Camila Pasquini de Souza
HMHelen de Morais
Helen de Morais
JZJanaina Menezes Zanoveli
Janaina Menezes Zanoveli